Evaxion Biotech A/S Profit Margin

Evaxion Biotech A/S posts a profit margin of -1.3% as of March 2026. That compares with -4.04% in the prior-year period — up 67.9% year over year. That is below the Healthcare sector average of 15.58%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Evaxion Biotech A/S's profit margin was -4.04%. The latest reading is -1.3% — a 67.9% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.58% is typical. Evaxion Biotech A/S's -1.3% is lower that level. That is roughly 932.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Evaxion Biotech A/S's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -1.3% as of March 2026; use YoY and peer views to separate noise from signal.

Context for EVAX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.58%), and (3) consistency with growth and profitability. This page covers the first two; Evaxion Biotech A/S's other metric pages and overview cover the third.